MA32018B1 - Vaccin - Google Patents
VaccinInfo
- Publication number
- MA32018B1 MA32018B1 MA33017A MA33017A MA32018B1 MA 32018 B1 MA32018 B1 MA 32018B1 MA 33017 A MA33017 A MA 33017A MA 33017 A MA33017 A MA 33017A MA 32018 B1 MA32018 B1 MA 32018B1
- Authority
- MA
- Morocco
- Prior art keywords
- gag
- hiv
- immunogenic
- cysteine
- component
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/5555—Muramyl dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Constituant de vaccin anti-vih comprenant: (a) une protéine de fusion immunogène comprenant nef ou son fragment immunogène ou son dérivé et p17 gag et/ou p24 gag ou leurs fragments immunogènes ou leurs dérivés, au moins un antigène ou un fragment immunogène de vih étant placé entre p17 et p24 gag, dans le cas de la présence de ces derniers; (b) un agent stabilisant sélectionné dans le groupe consistant en monothioglycérol, cystéine, n-acétyl cystéine ou leurs mélanges. L'invention concerne également des vaccins anti-vih contenant ledit constituant, ainsi que l'utilisation desdits vaccins pour la prophylaxie et le traitement du vih.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1576707P | 2007-12-21 | 2007-12-21 | |
US1995108P | 2008-01-09 | 2008-01-09 | |
PCT/EP2008/067945 WO2009080719A1 (fr) | 2007-12-21 | 2008-12-18 | Vaccin |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32018B1 true MA32018B1 (fr) | 2011-01-03 |
Family
ID=40577907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA33017A MA32018B1 (fr) | 2007-12-21 | 2010-07-14 | Vaccin |
Country Status (16)
Country | Link |
---|---|
US (2) | US20100285051A1 (fr) |
EP (1) | EP2247307A1 (fr) |
JP (2) | JP2011506565A (fr) |
KR (1) | KR20100109555A (fr) |
CN (1) | CN101951950A (fr) |
AU (1) | AU2008339984A1 (fr) |
BR (1) | BRPI0821555A2 (fr) |
CA (1) | CA2708718A1 (fr) |
CO (1) | CO6290701A2 (fr) |
CR (1) | CR11575A (fr) |
DO (1) | DOP2010000188A (fr) |
EA (1) | EA201000829A1 (fr) |
IL (1) | IL206307A0 (fr) |
MA (1) | MA32018B1 (fr) |
WO (1) | WO2009080719A1 (fr) |
ZA (1) | ZA201004303B (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011026111A1 (fr) | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Distribution par voie orale d'un vaccin au gros intestin pour induire une immunité mucosale |
EP2556377B1 (fr) | 2010-04-08 | 2017-07-12 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Analyse de cellules présentatrices d'antigène des lymphocytes b |
US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
WO2014113634A1 (fr) * | 2013-01-17 | 2014-07-24 | University Of Kansas | Lipopeptides agonistes du récepteur 2 de type toll, et procédé de fabrication de ceux-ci |
CN103330935A (zh) * | 2013-06-17 | 2013-10-02 | 中山大学 | 果糖作为疫苗佐剂的应用 |
GB201318862D0 (en) * | 2013-10-25 | 2013-12-11 | Glaxosmithkline Biolog Sa | Calcium fluoride compositions |
GB201318858D0 (en) * | 2013-10-25 | 2013-12-11 | Glaxosmithkline Biolog Sa | Calcium fluoride compositions |
WO2017144359A1 (fr) | 2016-02-22 | 2017-08-31 | Boehringer Ingelheim Vetmedica Gmbh | Procédé d'immobilisation de biomolécules |
EP3773708A2 (fr) * | 2018-04-03 | 2021-02-17 | Sanofi | Polypeptides antigéniques du virus d'epstein-barr |
CN112584858A (zh) | 2018-04-03 | 2021-03-30 | 赛诺菲 | 抗原性ospa多肽 |
CN112512564A (zh) | 2018-04-03 | 2021-03-16 | 赛诺菲 | 铁蛋白蛋白 |
MX2021001479A (es) * | 2018-08-07 | 2021-04-28 | Glaxosmithkline Biologicals Sa | Novedosos procesos y vacunas. |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4464474A (en) * | 1980-07-09 | 1984-08-07 | Connaught Laboratories Limited | Non-A, non-B hepatitis assay and vaccine |
CA2075521C (fr) * | 1992-05-05 | 1995-11-28 | Kuniaki Koyama | Vaccin vivant stabilise |
US5888516A (en) * | 1994-05-16 | 1999-03-30 | Merck & Co. Inc. | Recombinant papillomavirus vaccines |
ATE316139T1 (de) * | 1998-07-31 | 2006-02-15 | Akzo Nobel Nv | Attenuierte pferdeherpesvirus |
AU2001286996A1 (en) * | 2000-08-31 | 2002-03-13 | Chiron Corporation | Stabilized fgf formulations containing reducing agents |
FR2813756B1 (fr) * | 2000-09-11 | 2003-03-07 | Imv Technologies | Dilueur pour la conservation de spermatozoides de porcins |
EP1434859A2 (fr) * | 2001-07-25 | 2004-07-07 | New York University | Utilisation de glycosylceramides comme adjuvants pour des vaccins contre les infections et le cancer |
JP2005525344A (ja) * | 2002-02-04 | 2005-08-25 | コリクサ コーポレイション | アミノアルキルグルコサミニドホスフェートおよびサポニンを含む免疫刺激性組成物 |
US20030215455A1 (en) * | 2002-05-14 | 2003-11-20 | Bailey Reynolds | Vaccine stabilizer and method of use |
GB0300427D0 (en) * | 2003-01-09 | 2003-02-05 | Univ Strathclyde | Pharmaceutical composition |
EP1708742A4 (fr) * | 2003-12-05 | 2008-11-05 | Becton Dickinson Co | Procedes pour ameliorer la reponse immunitaire dans une partie intradermique et composes utilises dans ces procedes |
GB0417494D0 (en) * | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
US20060121055A1 (en) * | 2004-12-06 | 2006-06-08 | Becton, Dickinson And Company, Inc. | Compositions with enhanced immunogenicity |
-
2008
- 2008-12-18 CN CN2008801274463A patent/CN101951950A/zh active Pending
- 2008-12-18 AU AU2008339984A patent/AU2008339984A1/en not_active Abandoned
- 2008-12-18 US US12/809,774 patent/US20100285051A1/en not_active Abandoned
- 2008-12-18 JP JP2010538736A patent/JP2011506565A/ja active Pending
- 2008-12-18 EA EA201000829A patent/EA201000829A1/ru unknown
- 2008-12-18 EP EP08865759A patent/EP2247307A1/fr not_active Withdrawn
- 2008-12-18 BR BRPI0821555-3A patent/BRPI0821555A2/pt not_active IP Right Cessation
- 2008-12-18 CA CA2708718A patent/CA2708718A1/fr not_active Abandoned
- 2008-12-18 WO PCT/EP2008/067945 patent/WO2009080719A1/fr active Application Filing
- 2008-12-18 KR KR1020107016352A patent/KR20100109555A/ko not_active Application Discontinuation
-
2010
- 2010-06-10 IL IL206307A patent/IL206307A0/en unknown
- 2010-06-11 CO CO10071038A patent/CO6290701A2/es not_active Application Discontinuation
- 2010-06-17 ZA ZA2010/04303A patent/ZA201004303B/en unknown
- 2010-06-18 DO DO2010000188A patent/DOP2010000188A/es unknown
- 2010-07-14 MA MA33017A patent/MA32018B1/fr unknown
- 2010-07-21 CR CR11575A patent/CR11575A/es not_active Application Discontinuation
-
2013
- 2013-11-21 US US14/086,038 patent/US20140193481A1/en not_active Abandoned
-
2014
- 2014-08-01 JP JP2014157337A patent/JP2015007067A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2708718A1 (fr) | 2009-07-02 |
ZA201004303B (en) | 2011-11-30 |
JP2015007067A (ja) | 2015-01-15 |
DOP2010000188A (es) | 2010-10-31 |
IL206307A0 (en) | 2010-12-30 |
EA201000829A1 (ru) | 2011-06-30 |
KR20100109555A (ko) | 2010-10-08 |
EP2247307A1 (fr) | 2010-11-10 |
AU2008339984A1 (en) | 2009-07-02 |
BRPI0821555A2 (pt) | 2015-06-16 |
US20140193481A1 (en) | 2014-07-10 |
CN101951950A (zh) | 2011-01-19 |
WO2009080719A1 (fr) | 2009-07-02 |
CR11575A (es) | 2010-09-29 |
CO6290701A2 (es) | 2011-06-20 |
JP2011506565A (ja) | 2011-03-03 |
US20100285051A1 (en) | 2010-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32018B1 (fr) | Vaccin | |
NO20072733L (no) | Doseformer | |
PE20060149A1 (es) | Formulacion farmaceutica para tratar la infeccion por vih | |
PE20060148A1 (es) | Composicion farmaceutica para tratar la infeccion por vih | |
PE20070499A1 (es) | Composicion inmunogenica | |
NO20064584L (no) | Tetrahydropyridoindolderivater | |
AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
MA27699A1 (fr) | Vaccin contre vhc | |
EA200001030A1 (ru) | Получение капсул и таблеток быстрорастворяющегося эфавиренза с использованием супердезинтеграторов | |
NO20073764L (no) | Sammensetninger for behandling av HCV | |
MA29378B1 (fr) | Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer | |
MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
MA38567A1 (fr) | Variantes de pertuzumab et leur évaluation | |
DK1255815T3 (da) | Porcint reproduktivt og respiratorisk syndromvirus til fremgangsmåder til anvendelse | |
MA30670B1 (fr) | Vaccins contre le paludisme | |
BR0204470A (pt) | Uso de flavivirus para a expressão de epitopos de proteìna e para o desenvolvimento de um novo virus vacinal vivo atenuado para imunização contra flavivirus e outros agentes infecciosos | |
DE602005023342D1 (en) | S (porcine reproductive und respiratory syndrome) von schweinen | |
MX2023002233A (es) | Compuestos fosfolipidos y usos de estos. | |
BRPI0514724A (pt) | inibidores da enzima hiv integrase | |
ATE458496T1 (de) | Hiv-vakzine und anwendungsverfahren | |
NO20073071L (no) | Benzotiazolformuleringer og anvendelse av disse | |
AR054259A1 (es) | Vacuna contra virus de papiloma humano (hpv) | |
NO20065471L (no) | Anvendelse av IL-6 for behandling eller forebygging av kjemoterapiindusert nevropati. | |
MX2007009914A (es) | Uso de agonistas selectivos para el receptor-beta de estrogeno para la mucositis inducida por radiacion o por quimioterapia y para la cistitis inducida por radiacion. | |
BRPI0413906A (pt) | composições imunogênicas de hiv, kit e métodos relacionados |